Passage BIO, Inc.
PASGNasdaq
$4.83
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -13.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.5M
Enterprise Value
-$17.9M
P/E
—
P/S
—
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$38.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-324.7%
ROIC
—
Debt / Equity
—
Net Cash
$33.3M
Return 1Y
-16.3%
Company profile
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysososomal acid beta-galactosidase for infantile GM1. The company also develops PBML04 for the treatment of metachromatic leukodystrophy.
- CEO
- William Chou
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 130
- Headquarters
- Pennsylvania
- Website
- passagebio.com
Management & directors
- Borthwick KathleenCFO
- Chou WilliamPRESIDENT AND CEO
Roles derived from SEC Form 4 filings.
Earnings
PASG Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$2.36↓ -51.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$112.9M | -$185.7M | -$138.4M | -$108.4M | -$70.4M | -$49.3M |
| Net income | -$112.2M | -$185.4M | -$136.1M | -$102.1M | -$65.0M | -$46.0M |
| Diluted EPS | -$2.91 | -$3.48 | -$2.50 | -$1.86 | -$21.04 | -$14.35 |
| Operating cash flow | -$80.5M | -$126.9M | -$118.2M | -$78.3M | -$48.0M | -$31.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.4M | -$20.7M | -$14.3M | -$16.5M | -$10.3M | -$8.7M | -$13.8M | -$8.2M |
| Net income | -$16.0M | -$19.3M | -$13.0M | -$15.4M | -$9.4M | -$7.7M | -$13.5M | -$7.6M |
| Diluted EPS | -$5.09 | -$6.15 | -$9.50 | -$4.87 | -$2.96 | -$2.44 | -$4.08 | -$2.36 |
| Operating cash flow | -$13.1M | -$7.4M | -$8.4M | -$13.8M | -$6.3M | -$4.9M | -$6.5M | -$13.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 25, 2026
Jun 24, 2026
May 20, 2026
Apr 21, 2026
- 90d agoSector Update: Health Care Stocks Softer Late Afternoonfinance.yahoo.com
- 90d agoPassage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Saysfinance.yahoo.com
- 90d agoPassage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Saysfinance.yahoo.com
- 90d agoIntel upgraded, Reddit initiated: Wall Street's top analyst callsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-25 | Lynx1 Capital Management LP | Buy | 50,055 | $4.12 | $206,101.46 | filing |
| 2026-01-08 | Chou William· PRESIDENT AND CEO | Sale | 4,076 | $18.44 | $75,158.99 | filing |
| 2026-01-08 | Borthwick Kathleen· CFO | Sale | 2,062 | $18.44 | $38,022.04 | filing |
| 2026-01-08 | Borthwick Kathleen· CFO | Option exercise | 5,000 | — | — | filing |
| 2026-01-08 | Chou William· PRESIDENT AND CEO | Option exercise | 10,000 | — | — | filing |
| 2025-09-15 | Lynx1 Capital Management LP | Buy | 11,900 | $6.99 | $83,175.05 | filing |
| 2025-09-12 | Lynx1 Capital Management LP | Buy | 19,783 | $6.99 | $138,299.00 | filing |
| 2025-09-11 | Lynx1 Capital Management LP | Buy | 325 | $6.96 | $2,260.64 | filing |
| 2025-07-24 | Lynx1 Capital Management LP | Buy | 66,423 | $5.71 | $379,454.67 | filing |
| 2025-07-23 | Lynx1 Capital Management LP | Buy | 49,302 | $5.74 | $283,032.92 | filing |
| 2025-07-22 | Lynx1 Capital Management LP | Buy | 13,123 | $5.44 | $71,337.94 | filing |
| 2025-06-26 | ORBIMED ADVISORS LLC | Sale | 213,257 | $0.33 | $70,374.81 | filing |
| 2025-06-25 | ORBIMED ADVISORS LLC | Sale | 138,800 | $0.33 | $45,804.00 | filing |
| 2025-06-24 | ORBIMED ADVISORS LLC | Sale | 231,600 | $0.35 | $81,060.00 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.